SG11201908660RA - N-substituted indole derivatives - Google Patents
N-substituted indole derivativesInfo
- Publication number
- SG11201908660RA SG11201908660RA SG11201908660RA SG11201908660RA SG 11201908660R A SG11201908660R A SG 11201908660RA SG 11201908660R A SG11201908660R A SG 11201908660RA SG 11201908660R A SG11201908660R A SG 11201908660RA
- Authority
- SG
- Singapore
- Prior art keywords
- idorsia
- hegenheimermattweg
- allschwil
- international
- pharmaceuticals
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COOHR (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 November 2018 (22.11.2018) WIP0 I PCT 01E1°1°1a °nolo III 0111010lionoin num oimIE (10) International Publication Number WO 2018/210995 Al (51) International Patent Classification: CO7D 403/12 (2006.01) A61K 31/675 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2018/062865 (22) International Filing Date: 17 May 2018 (17.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/EP2017/062008 18 May 2017 (18.05.2017) EP (71) Applicant: IDORSIA PHARMACEUTICALS LTD [CH/CH]; Hegenheimermattweg 91, 4123 Allschwil (CH). (72) Inventors: FRETZ, Heinz; Oertli 40c, 3654 Gun- ten (CH). LYOTHIER, Isabelle; c/o Idorsia Pharma- ceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). POTHIER, Julien; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). RICHARD-BILDSTEIN, Sylvia; c/o Idorsia Pharmaceu- ticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). SIFFERLEN, Thierry; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). Agent: VELKER, Jorg; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) (54) Title: N-SUBSTITUTED INDOLE DERIVATIVES O 00 Formula (I) (57) : The present invention relates to derivatives of formula (I) Formula (I) wherein R 1 , and R 2 are as described in the ei description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptor EP2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017062008 | 2017-05-18 | ||
| PCT/EP2018/062865 WO2018210995A1 (en) | 2017-05-18 | 2018-05-17 | N-substituted indole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908660RA true SG11201908660RA (en) | 2019-10-30 |
Family
ID=62186481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908660R SG11201908660RA (en) | 2017-05-18 | 2018-05-17 | N-substituted indole derivatives |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20200069686A1 (en) |
| EP (1) | EP3625224B1 (en) |
| JP (1) | JP7065117B2 (en) |
| KR (1) | KR102650756B1 (en) |
| CN (1) | CN110621666A (en) |
| AR (1) | AR111806A1 (en) |
| AU (1) | AU2018269667B2 (en) |
| BR (1) | BR112019024114A2 (en) |
| CA (1) | CA3063637A1 (en) |
| CL (1) | CL2019003257A1 (en) |
| CO (1) | CO2019010804A2 (en) |
| CR (1) | CR20190567A (en) |
| CY (1) | CY1124528T1 (en) |
| DK (1) | DK3625224T3 (en) |
| EA (1) | EA039630B1 (en) |
| ES (1) | ES2894124T3 (en) |
| HR (1) | HRP20211532T1 (en) |
| HU (1) | HUE056406T2 (en) |
| IL (1) | IL270616B (en) |
| LT (1) | LT3625224T (en) |
| MA (1) | MA49127B1 (en) |
| MX (1) | MX2019013639A (en) |
| PE (1) | PE20191787A1 (en) |
| PH (1) | PH12019502562A1 (en) |
| PL (1) | PL3625224T3 (en) |
| PT (1) | PT3625224T (en) |
| RS (1) | RS62441B1 (en) |
| SG (1) | SG11201908660RA (en) |
| SI (1) | SI3625224T1 (en) |
| TW (1) | TWI768043B (en) |
| UA (1) | UA124748C2 (en) |
| WO (1) | WO2018210995A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (en) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | DERIVATIVES OF INDOL N-SUBSTITUTES AS MODULATORS OF PGE2 RECEIVERS |
| ES2893452T3 (en) | 2017-05-18 | 2022-02-09 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| TW201900180A (en) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | Pyrimidine derivative |
| CA3063632A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| MA49128A (en) | 2017-05-18 | 2021-03-17 | Idorsia Pharmaceuticals Ltd | PYRIMIDINE DERIVATIVES USED AS MODULATORS OF PGE2 RECEPTORS |
| WO2021060281A1 (en) * | 2019-09-24 | 2021-04-01 | Ａｇｃ株式会社 | Prostaglandin e2 receptor ep2/ep4 dual antagonist |
| CN115697317A (en) * | 2020-04-08 | 2023-02-03 | 株式会社AskAt | Use of EP4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia |
| KR20230107228A (en) | 2020-11-13 | 2023-07-14 | 오노 야꾸힝 고교 가부시키가이샤 | Cancer treatment by combination of EP4 antagonists and immune checkpoint inhibitors |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2402099C (en) | 2000-03-24 | 2011-04-26 | Pharmagene Laboratories Ltd. | Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment |
| HN2001000224A (en) | 2000-10-19 | 2002-06-13 | Pfizer | IMIDAZOL COMPOUNDS CONDENSED WITH ARILO OR HETEROARILO AS ANTI - INFLAMMATORY AND ANALGESIC AGENTS. |
| GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| BR0309305A (en) | 2002-04-12 | 2005-02-15 | Pfizer | Imidazole compounds as anti-inflammatory and analgesic agents |
| MXPA04009960A (en) | 2002-04-12 | 2004-12-13 | Pfizer | Pyrazole compounds as anti-inflammatory and analgesic agents. |
| WO2003099857A1 (en) | 2002-05-23 | 2003-12-04 | Theratechnologies Inc. | Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
| KR101094003B1 (en) | 2003-01-29 | 2011-12-15 | 아스터랜드 유케이 리미티드 | Ep4 receptor antagonists |
| MXPA06002001A (en) * | 2003-08-26 | 2006-06-20 | Teijin Pharma Ltd | Pyrrolopyrimidinone derivative. |
| ES2441206T3 (en) | 2003-09-03 | 2014-02-03 | Raqualia Pharma Inc. | Phenyl or pyridylamide compounds as prostaglandin E2 antagonists |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| CA2565660C (en) | 2004-05-04 | 2009-11-03 | Pfizer Inc. | Ortho substituted aryl or heteroaryl amide compounds |
| JP4054368B2 (en) | 2004-05-04 | 2008-02-27 | ファイザー株式会社 | Substituted methylaryl or heteroarylamide compounds |
| HN2005000795A (en) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | PYRIMIDINS AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEPTOR |
| ATE533766T1 (en) | 2005-05-19 | 2011-12-15 | Merck Canada Inc | QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| JP5244091B2 (en) | 2006-04-24 | 2013-07-24 | メルク カナダ インコーポレイテッド | Indoleamide derivatives as EP4 receptor antagonists |
| US7705035B2 (en) | 2006-06-12 | 2010-04-27 | Merck Frosst Canada Ltd. | Indoline amide derivatives as EP4 receptor ligands |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| PT2044056E (en) | 2006-07-14 | 2012-12-05 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
| US8969394B2 (en) | 2006-08-11 | 2015-03-03 | Merck Frosst Canada Ltd. | Thiophenecarboxamide derivatives as EP4 receptor ligands |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| CA2679175C (en) | 2007-02-26 | 2015-01-13 | Merck Frosst Canada Ltd. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| JP2010522218A (en) | 2007-03-26 | 2010-07-01 | メルク フロスト カナダ リミテツド | Naphthalene and quinolinesulfonylurea derivatives as EP4 receptor antagonists |
| KR20090122931A (en) | 2007-03-26 | 2009-12-01 | 아스테라스 세이야쿠 가부시키가이샤 | Ornithine derivative |
| EP2014657A1 (en) | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidines as modulators for an EP2 receptor |
| EP2172447A4 (en) | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | Amide compound |
| DK2565191T3 (en) | 2008-05-14 | 2014-11-10 | Astellas Pharma Inc | 4- (Indol-7-ylcarbonylaminomethyl) cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy |
| WO2010019796A1 (en) | 2008-08-14 | 2010-02-18 | Chemietek, Llc | Heterocyclic amide derivatives as ep4 receptor antagonists |
| GB2474813B (en) | 2008-09-19 | 2014-05-28 | Biotechnology Res Corp Ltd | Triterpenoid compounds and methods of use thereof |
| WO2010034110A1 (en) | 2008-09-25 | 2010-04-01 | Merck Frosst Canada Ltd. | Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists |
| JP5607241B2 (en) | 2010-05-21 | 2014-10-15 | ケミリア・エービー | New pyrimidine derivatives |
| ES2610185T3 (en) | 2010-09-21 | 2017-04-26 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
| KR101857310B1 (en) | 2010-09-29 | 2018-05-11 | 가부시키가이샤 에누비 켄코우겡큐쇼 | Antibody against human prostaglandin e2 receptor ep4 |
| ES2545110T3 (en) | 2010-12-10 | 2015-09-08 | Rottapharm Biotech S.R.L. | Pyridinamide derivatives as EP4 receptor antagonists |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
| AU2012230229A1 (en) | 2011-03-24 | 2013-10-10 | Noviga Research Ab | Novel pyrimidine derivatives |
| PL2729445T3 (en) | 2011-07-04 | 2016-04-29 | Rottapharm Biotech Srl | Cyclic amine derivatives as ep4 receptor antagonists |
| EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
| WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| PT2841428T (en) | 2012-04-24 | 2018-11-29 | Vertex Pharma | Dna-pk inhibitors |
| AR091429A1 (en) | 2012-06-29 | 2015-02-04 | Lilly Co Eli | PIPERIDINE PHENOXIETIL COMPOUNDS |
| TWI572597B (en) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | Dimethyl-benzoic acid compounds |
| UA115576C2 (en) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | BENZIMIDASOL DERIVATIVES AS ER4 ANGAGONES |
| EP2765128A1 (en) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TW201443004A (en) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | Phenoxyethoxy compounds |
| TWI636046B (en) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | Phenoxyethyl dihydro-1h-isoquinoline compounds |
| MX369804B (en) | 2013-06-12 | 2019-11-21 | Kaken Pharma Co Ltd | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient. |
| AU2014315457B2 (en) | 2013-09-04 | 2018-05-10 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| ES2788848T3 (en) | 2013-09-06 | 2020-10-23 | Aurigene Discovery Tech Ltd | 1,2,4-Oxadiazole derivatives as immunomodulators |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| SI3057959T1 (en) | 2013-10-17 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| CA2929562A1 (en) | 2013-12-17 | 2015-06-25 | Eli Lilly And Company | Dimethylbenzoic acid compounds |
| ES2651858T3 (en) | 2013-12-17 | 2018-01-30 | Eli Lilly & Company | Phenoxyethyl cyclic amine derivatives and their activity as modulators of the EP4 receptor |
| TW201607943A (en) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | Novel benzimidazole derivatives as EP4 ligands |
| TW201623277A (en) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | Amide compound |
| JP6787792B2 (en) | 2014-05-23 | 2020-11-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Combination treatment for the treatment of cancer |
| WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| WO2016054807A1 (en) * | 2014-10-10 | 2016-04-14 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| TWI812496B (en) | 2015-01-09 | 2023-08-11 | 日商小野藥品工業股份有限公司 | Use of tricyclic spiro compound |
| WO2017014323A1 (en) | 2015-07-23 | 2017-01-26 | Takeda Pharmaceutical Company Limited | 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists |
| CN108473497B (en) | 2015-10-16 | 2021-09-10 | 卫材R&D 管理有限公司 | EP4 antagonists |
-
2018
- 2018-05-17 PE PE2019002413A patent/PE20191787A1/en unknown
- 2018-05-17 CR CR20190567A patent/CR20190567A/en unknown
- 2018-05-17 RS RS20211259A patent/RS62441B1/en unknown
- 2018-05-17 BR BR112019024114-0A patent/BR112019024114A2/en unknown
- 2018-05-17 JP JP2019563494A patent/JP7065117B2/en active Active
- 2018-05-17 PL PL18725223T patent/PL3625224T3/en unknown
- 2018-05-17 CN CN201880031869.9A patent/CN110621666A/en active Pending
- 2018-05-17 SI SI201830413T patent/SI3625224T1/en unknown
- 2018-05-17 EA EA201992679A patent/EA039630B1/en unknown
- 2018-05-17 MX MX2019013639A patent/MX2019013639A/en unknown
- 2018-05-17 HU HUE18725223A patent/HUE056406T2/en unknown
- 2018-05-17 ES ES18725223T patent/ES2894124T3/en active Active
- 2018-05-17 HR HRP20211532TT patent/HRP20211532T1/en unknown
- 2018-05-17 EP EP18725223.4A patent/EP3625224B1/en active Active
- 2018-05-17 WO PCT/EP2018/062865 patent/WO2018210995A1/en unknown
- 2018-05-17 KR KR1020197037058A patent/KR102650756B1/en active IP Right Grant
- 2018-05-17 UA UAA201911973A patent/UA124748C2/en unknown
- 2018-05-17 PT PT18725223T patent/PT3625224T/en unknown
- 2018-05-17 AU AU2018269667A patent/AU2018269667B2/en active Active
- 2018-05-17 MA MA49127A patent/MA49127B1/en unknown
- 2018-05-17 US US16/614,268 patent/US20200069686A1/en not_active Abandoned
- 2018-05-17 CA CA3063637A patent/CA3063637A1/en active Pending
- 2018-05-17 LT LTEPPCT/EP2018/062865T patent/LT3625224T/en unknown
- 2018-05-17 TW TW107116708A patent/TWI768043B/en active
- 2018-05-17 DK DK18725223.4T patent/DK3625224T3/en active
- 2018-05-17 SG SG11201908660R patent/SG11201908660RA/en unknown
- 2018-05-17 AR ARP180101311A patent/AR111806A1/en unknown
-
2019
- 2019-09-30 CO CONC2019/0010804A patent/CO2019010804A2/en unknown
- 2019-11-13 IL IL270616A patent/IL270616B/en unknown
- 2019-11-14 CL CL2019003257A patent/CL2019003257A1/en unknown
- 2019-11-15 PH PH12019502562A patent/PH12019502562A1/en unknown
-
2021
- 2021-09-27 CY CY20211100841T patent/CY1124528T1/en unknown
-
2022
- 2022-11-27 US US18/058,873 patent/US20230165859A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908660RA (en) | N-substituted indole derivatives | |
| SG11201908729UA (en) | Phenyl derivatives as pge2 receptor modulators | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201908097YA (en) | Pyrimidine derivatives as pge2 receptor modulators | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201908977SA (en) | Niraparib formulations | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201906767XA (en) | Estrogen receptor modulators | |
| SG11201806480UA (en) | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer | |
| SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries |